Seeking Alpha ' 62 WEEK DATA TO PROPEL SHARES, MEANS EARLY APPROVAL.LINKED
Biotech Stocks With Important Catalysts Approaching
December 5, 2012
Sarepta will announce 60 week clinical data confirming the 48 week data and seek accelerated approval from the FDA for eteplirsen. The release of the 60 week data could occur anytime and, if positive, would certainly propel the stock and give Sarepta more leverage for accelerated approval from the FDA.